Table 5.

Targeted agents—Miscellaneous (10 trials).

Treatment Regimen	Ph	N	Age Range (Years)	OST pts	PR	SD	DC Duration	Comments	Reference
Talazoparib + TMZ	I	40	4–25	4	0	0	-	-	Schafer et al., 2020 [76]
glembatumumab vedotin (GV)	II	22	12–31	22	1/22 (4.5%)	2/22 (9%)	4 mo	Strong gpNMB expression in 15/21 (68%) of pts	Kopp et al., 2019 [17]
Cixutumumab monotherapy	II	102	2–30	11	0	1/11 (9%)	5 mo	-	Weigel et al., 2014 [79]
R1507	II	163	7–85	38	2/38 (5%)	10/38 (26%)	NS	Overall mPFS: 5.7 wks (5.6–5.9) mOS: 11 (9.4–13.1)	Pappo et al., 2014 [80]
Imetelstat (oligonucleotide)	I	20	3–21	6	1/6 (17%)	NS	NS	Telomerase inhibition confirmed by Western Blot	Thompson et al., 2013 [81]
Lexatumumab	I	24	2–21	9	0	NS	24 mo	metabolic response in 1/9 OST pt (11%)	Merchant et al., 2012 [82]
RG1507	I	31	3–17	3	0	2/3 (66%)	Beyond 52 and 78 wks	-	Bagatell et al., 2011 [83]
Rexin-G	I/II	42	7–68	22	0	10/17 (59%)	≥3 mo	metabolic response in 4/17 (24%) of OST pts mPFS ≥3 mo mOS 6.9 mo	Chawla et al., 2009 [84]
17-AAG	I	15	4–21	6	0	0	-	2 OST pts with lung metastases died at cy 1	Bagatell et al., 2007 [85]
ecteinascidin 743	II	25	12–67	25	0	6/23 (24%)	2–4 mo	Minor response in 3/23 (12%) OST pts	Laverdiere et al., 2003 [28]